Skip to main content

Advertisement

Table 3 Univariate Cox regression analyses of systemic-recurrence-free survival and breast-cancer specific survival

From: Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome

BM samples Parameter Hazard ratio 95% CI P-values
  Systemic recurrence-free survival    
BM1 DTC status (pos. vs. neg.) 5.944 2.713–13.022 <0.001
BM2* DTC status (pos. vs. neg.) 5.013 2.133–11.782 <0.001
BM3* DTC status (pos. vs. neg.) 3.680 1.062–12.744 0.040
BM2 and/or BM3 DTC status (pos. vs. neg.) 4.523 2.044–10.008 <0.001
BM1 and BM2/3 DTC status (pos. vs. neg.) 9.948 4.103–24.122 <0.001
  Lymph node status (pN > 0 vs. pN0) 3.995 1.833–8.708 <0.001
  Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.523 0.691–3.358 0.297
  Tumor grade (3 vs. 2 vs. 1) 2.015 1.212–3.352 0.007
  Age (>55 or not) 1.044 0.484–2.252 0.913
  ER (positive vs. negative) 0.322 0.143–0.723 0.006
  PgR (positive vs. negative) 0.735 0.337–1.605 0.440
  Adjuvant chemotherapy (received or not) 1.603 0.713–3.601 0.253
  Adjuvant endocrine therapy (received or not) 1.814 0.832–3.951 0.134
  Breast-cancer specific survival    
BM1 DTC status (pos. vs. neg.) 5.408 2.271–12.880 <0.001
BM2* DTC status (pos. vs. neg.) 3.880 1.470–10.238 0.006
BM3* DTC status (pos. vs. neg.) 4.626 1.286–16.635 0.019
BM2 and/or BM3 DTC status (pos. vs. neg.) 3.851 1.592–9.316 0.003
BM1 and BM2/3 DTC status (pos. vs. neg.) 9.205 3.526–24.031 <0.001
  Lymph node status (pN > 0 vs. pN0) 4.694 1.944–11.344 0.001
  Tumor size (pT3 and pT4 vs. pT2 vs. pT1) 1.788 0.753–4.247 0.188
  Tumor grade (3 vs. 2 vs. 1) 3.288 1.743–6.201 <0.001
  Age (>55 or not) 1.384 0.583–3.284 0.461
  ER (positive vs. negative) 0.217 0.091–0.516 0.001
  PgR (positive vs. negative) 0.729 0.306–1.733 0.474
  Adjuvant chemotherapy (received or not) 1.545 0.623–3.833 0.348
  Adjuvant endocrine therapy (received or not) 1.820 0.766–4.324 0.175
  1. BM1 drawn prior to surgery, BM2 drawn three weeks after surgery, BM3 drawn six months after surgery;BM bone marrow; DTC disseminated tumor cell; ER Estrogen receptor; PgR Progesterone receptor; BM2/3 BM2 and/or BM3.
  2. *only patients with this sample available were included in the analysis.